Colchicine has been shown to effectively suppress interleukin IL-1b, IL-18 and IL-6 in patients with acute coronary syndrome [42, 43] and is now being trialed in COVID-19 ARDS, albeit it also has very significant side effects [39]. Here, IL6 is linked to acute coronary syndrome.